BRISBANE, Australia, Sept. 30, 2026 (GLOBE NEWSWIRE) — North American lithium producer Elevra Lithium Limited (“Elevra” or “Company”) (ASX:ELV; NASDAQ:ELVR) announces the following indicative key dates for the 2026 Annual General Meeting:

Date Event
8 October 2026 (AEST) Last date for nomination of Directors
16 October 2026 (AEST) Release of 2026 Notice of Annual General Meeting
19 November 2026 (AEST) 2026 Annual General Meeting
   

Shareholders will be provided with information on how to participate in the 2026 Annual General Meeting when the Notice of Meeting is released on 16 October 2026.

Announcement authorised for release by Elevra’s Managing Director & Chief Executive Officer.

About Elevra Lithium

Elevra Lithium Limited is a North American lithium producer (ASX:ELV; NASDAQ:ELVR) with projects in Québec, Canada, United States, and a Joint Venture in Western Australia.

Elevra’s assets comprise North American Lithium (100%), a 60% stake in the Moblan Lithium Project in Central Québec and the Carolina Lithium project (100%) in the United States.

For more information, please visit us at www.elevra.com or contact:

Andrew Barber
Investor Relations
PH: +617 3369 7058

September 30, 2026 /3BL/ – Medtronic today announced it has been named to the prestigious FORTUNE 2026 ‘Change the World’ list for its Touch Surgery™ ecosystem and Healthy Neighbor program through Medtronic LABS. The annual list showcases companies working to combat global issues and drive positive social or environmental change.

The recognition highlights how Medtronic is harnessing technology to improve healthcare outcomes from the operating room to underserved communities.

Touch Surgery™ ecosystem transforms the future of surgery
The Touch Surgery TM ecosystem uses AI to analyze surgery and enables livestreaming for remote collaboration, helping physicians review procedures and improve surgical practices. Connecting the full surgical journey from planning and training to intraoperative collaboration, Touch Surgery now supports thousands of surgeons in 30+ countries worldwide. Announced in July 2026, Touch SurgeryTM Aide, the next-generation compute platform for the operating rooms, extends the platform by adding AI-powered, real-time support. This helps surgeons access actionable insights during robotic and laparoscopic procedures while enabling teams to review cases and continuously improve surgical decision-making.

“Our vision is to make the best surgery available to more people, regardless of where they live,” said Matt Anderson, senior vice president and president, Surgical business at Medtronic. “The Touch Surgery TM ecosystem enables surgeons to deliver upon intelligence and perform procedures with greater consistency and confidence, helping to advance Medtronic’s commitment to expand access to the best possible care around the world.”

Medtronic LABS addresses health disparities with Virtua Health
In partnership with Virtua Health, the Healthy Neighbor program was designed to address chronic health disparities in Camden, New Jersey. Located just across the river from Philadelphia, Camden residents face a reduction in life expectancy of nearly 16 years compared to neighborhoods just 6.5 miles away. In particular, the rates of diabetes and high blood pressure in Camden are dramatically higher than in nearby communities.

Virtua Health partnered with Medtronic LABS, a nonprofit funded by Medtronic, to bring community health workers directly to the homes of those with high blood pressure and/or type 2 diabetes for ongoing healthcare coordination. Each team member is equipped with a digital health platform, streamlining their work by capturing basic healthcare information, tracking blood pressure and glucose over time, and flagging elevated readings for follow-up. After two years, results from more than 250 patients enrolled showed:

  • 74% of patients with uncontrolled hypertension achieved meaningful improvement, with an average 15-point drop in systolic blood pressure.
  • 69% of patients with uncontrolled diabetes achieved a meaningful improvement with a 1.2% mean drop in A1C.
  • These improvements in blood pressure and hemoglobin A1C control are linked to a significant reduction in debilitating long-term complications.1

“Being recognized is not just an honor, but an affirmation that our work at Medtronic to put patients first in every aspect of the business is making a meaningful impact,” said Ruchika Singhal, president of Medtronic LABS. “True innovation in healthcare should be comprehensive – from developing the technology itself to rethinking delivery models – and should improve health outcomes no matter your ZIP code or income.”

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

About Medtronic LABS

Medtronic LABS is a non-profit organization that develops community-based, tech-enabled solutions for underserved patients, families, and communities across the world. By bridging hyper-local services with cutting-edge technology, we provide sustainable and localized healthcare solutions that produce measurable outcomes for all. We have served patients through eight programs across sub-Saharan Africa, South Asia, and the United States. To date, we have screened nearly 2M individuals for chronic diseases, enrolled 414,000 in our management programs, and achieved measurable improvements in health and wellbeing for 219,000 patients.

www.medtroniclabs.org

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1Uncontrolled hypertension is defined as a baseline reading ≥140/90 (n=58). Uncontrolled diabetes is defined as baseline HbA1c ≥ 8% (n=26). Meaningful improvement in blood pressure is defined as achieving blood pressure control (<140/90) or a ≥10mmHg reduction in systolic blood pressure. Meaningful improvement in HbA1c is defined as achieving control (HbA1c <8%) or ≥1% reduction in HbA1c.

HOUSTON–(BUSINESS WIRE)–Gridmatic, an AI-first power company, today announced its retail business, Gridmatic Retail, has been named a price-competitiveness award winner in its first appearance in Energy Research Consulting Group’s (ERCG) annual ABC Study. The study benchmarks retail energy suppliers based on feedback from Aggregators, Brokers, and Consultants (ABCs) across the United States. In this year’s study, Gridmatic Retail won an ERCG Excellence Award in Price Competitiveness, and was

SAN DIEGO, Sept. 30, 2026 (GLOBE NEWSWIRE) — LPL Financial LLC announced today that financial advisors Harrison Kennard, CFP®, Charles Dobben and Justin Pandy, CFP®, of Lakewood Wealth Management have joined LPL Financial’s broker-dealer and Registered Investment Advisor (RIA) platforms. The team reported serving approximately $170 million in advisory, brokerage and retirement plan assets* and joins LPL from Cambridge.

Based in Ann Arbor, Mich., Lakewood Wealth Management serves successful professionals, families and retirees through a comprehensive planning approach centered on building long-term relationships. The team works with many multigenerational families, often helping grandparents, their children and grandchildren navigate important financial decisions together. Their client base also includes healthcare professionals, university faculty and student-athletes benefiting from Name, Image and Likeness (NIL) opportunities.

Founder Harrison Kennard brings nearly two decades of industry experience and leads a collaborative team alongside Charles Dobben and Justin Pandy. Together, the advisors focus on comprehensive financial planning, including tax planning, estate planning and wealth management strategies tailored to each client’s unique goals and circumstances.

“We believe financial planning is about much more than investments,” Kennard said. “Every client has a unique story, unique priorities and different goals. Our job is to understand what matters most to them and create a plan that helps support those objectives. Whether we’re working with a family across multiple generations, a healthcare professional or a young athlete navigating newfound opportunities, we want to serve as a trusted partner through every stage of life.”

Lakewood Wealth Management emphasizes personalized planning and ongoing collaboration with clients. The team works to understand each client’s full financial picture before developing strategies designed to evolve alongside changing needs and life circumstances. Their planning process integrates investment management with tax and estate considerations to help clients make confident decisions about their future.

The firm operates with a team-based structure in which Kennard collaborates closely with Dobben and Pandy. Together, they combine experience, education and diverse perspectives to help clients receive thoughtful guidance and personalized service.

Why Lakewood Wealth Management Chose LPL

The advisors selected LPL for its depth of resources, advanced technology capabilities and commitment to advisor independence. As they evaluated potential partners, the team sought a platform that would enhance the client experience while providing access to specialized expertise and expanded planning resources.

“We wanted a partner that would allow us to continue operating independently while giving us access to quality technology and resources,” Kennard said. “LPL’s platform provides the tools and support we need to create a better overall experience for our clients. The technology, planning capabilities and access to subject matter experts across a wide range of disciplines stood out to us, and we’re excited about the opportunities this move creates for both our team and the families we serve.”

Marc Cohen, Chief Growth Officer at LPL Financial, said, “Lakewood Wealth Management has built a practice centered on an important principle: every client’s goals, circumstances and aspirations are unique. Harrison, Charles, and Justin have distinguished themselves through thoughtful planning, personalized advice and a commitment to serving clients through every stage of life. We are honored they chose LPL and look forward to supporting their continued growth.”

Related

Advisors, learn how LPL Financial can help take your business to the next level.

About LPL Financial

LPL Financial Holdings Inc. (Nasdaq: LPLA) is among the fastest growing wealth management firms in the U.S. As a leader in the financial advisor-mediated marketplace, LPL supports more than 32,000 financial advisors and the wealth management practices of approximately 1,100 financial institutions, servicing and custodying approximately $2.6 trillion in brokerage and advisory assets on behalf of approximately 8 million Americans. The firm provides a wide range of advisor affiliation models, investment solutions, fintech tools and practice management services, ensuring that advisors and institutions have the flexibility to choose the business model, services, and technology resources they need to run thriving businesses. For further information about LPL, please visit www.lpl.com.

Securities and advisory services offered through LPL Financial LLC (“LPL Financial”), a registered investment advisor and broker-dealer, member FINRA/SIPC. Lakewood Wealth Management and LPL Financial are separate entities.

Throughout this communication, the terms “financial advisors” and “advisors” are used to refer to registered representatives and/or investment advisor representatives affiliated with LPL Financial.

We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

*Value approximated based on asset and holding details provided to LPL from end of year, 2025.

Media Contact: 
Media.relations@LPLFinancial.com  

Tracking #1181832

First party, direct-from-source Real World Data will feed the Company’s tenth channel partner’s AI models and a licensable derivative dataset that partner will sell

MINNEAPOLIS, Sept. 30, 2026 (GLOBE NEWSWIRE) — OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of First-Party (Direct-from-Source) regulatory decision-grade, AI-driven Real World Data (RWD), today announced a seven figure multiyear agreement to deliver de-identified, multimodal, longitudinal clinical Real World Data to a commercially scaled AI-enabled precision medicine company.

The data will be delivered to the customer through OneMedNet’s iRWD™ Platform. The customer intends to use the data to train AI-enabled clinical and diagnostic models and to create a licensable derivative dataset to sell into its own channel, linking the customer’s molecular datasets with OneMedNet’s first-party imaging and longitudinal clinical journeys. Combined, the derived product is designed to be more valuable and more actionable for life-sciences customer base than either source alone.

OneMedNet earns incremental annual sublicensing revenue each time that our solution is licensed to the customer’s end user in addition to the initial data license. The agreement includes an option to expand data volume and contract value.

The customer is a developer of AI-enabled precision medicine products with a well-established customer base in the life sciences. It selected OneMedNet’s first-party data sourced directly from a live network of more than 2,300 healthcare partner sites, not intermediaries or secondary markets. OneMedNet solutions applies de-identification at the source, at the scale and standards to enable AI training of evolving foundation models and to satisfy other life science commercial data needs.

“Sophisticated AI companies in healthcare are not buying one-time data pulls. They want a long-term source of multimodal, regulatory-grade data, direct from the source, at the quality required to build models and commercialize their data products,” said Aaron Green, President & CEO of OneMedNet. “That is this agreement: a seven figure multiyear license, plus a derivative dataset our partner will commercialize, with OneMedNet paid on every downstream license — multiyear licenses, sublicensing on solutions built with our data, and room to expand.”

Agreement highlights

  • Seven-figure, multiyear agreement, with an option to expand volume and value.
  • Customer-sold derivative dataset with OneMedNet’s tenth channel partner, and recurring sublicensing revenue to OneMedNet on each end-customer license.
  • First-party, direct-from-source data, de-identified at the source, from more than 2,300 partner sites.
  • OneMedNet retains source-data rights. End customers of the derivative may not relicense or resell the underlying OneMedNet data.

About OneMedNet Corporation

OneMedNet Corporation is revolutionizing Real World Data (RWD) through its iRWD™ platform, delivering regulatory decision-grade, AI-ready datasets that include de-identified medical imaging alongside comprehensive clinical records. With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data. The Company’s platform supports applications ranging from drug development and regulatory submissions to foundational AI model training.

Learn more at www.onemednet.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements. These statements include, but are not limited to statements regarding the benefits and capabilities of our products and the customer agreement, and statements generally about our products, plans and strategies.

Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include, but are not limited to: our ability to change the direction of OneMedNet; our ability to keep pace with new technology and changing market needs; the competitive environment of our business; the timing of customer acceptance and data delivery; and the other risks described in our most recent Annual Report on Form 10-K and our subsequent filings with the Securities and Exchange Commission. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

OneMedNet Contacts:

Michael Wong, VP Marketing
Email: michael.wong@onemednet.com

SOURCE: ONEMEDNET CORPORATION

8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE
Rule 8.3 of the Takeover Code (the “Code”)

1.        KEY INFORMATION

(a)   Full name of discloser: Rathbones Group Plc
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):
        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
 
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:
        Use a separate form for each offeror/offeree
NextEnergy Solar Fund Ltd
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:  
(e)   Date position held/dealing undertaken:
        For an opening position disclosure, state the latest practicable date prior to the disclosure
29/09/2026
(f)   In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?
        If it is a cash offer or possible cash offer, state “N/A”
No

2.        POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a)      Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: Ordinary NPV
  Interests Short positions
  Number % Number %
(1)   Relevant securities owned and/or controlled: 5,763,111 1.00%    
(2)   Cash-settled derivatives:        
(3)   Stock-settled derivatives (including options) and agreements to purchase/sell:        
        TOTAL: 5,763,111 1.00%    

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b)      Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:  
Details, including nature of the rights concerned and relevant percentages:  

3.        DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)        Purchases and sales

Class of relevant security Purchase/sale Number of securities Price per unit
Ordinary NPV Sale 30,550 48.872p

(b)        Cash-settled derivative transactions

Class of relevant security Product description
e.g. CFD
Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position
Number of reference securities Price per unit
         

(c)        Stock-settled derivative transactions (including options)

(i)        Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type
e.g. American, European etc.
Expiry date Option money paid/ received per unit
               

(ii)        Exercise

Class of relevant security Product description
e.g. call option
Exercising/ exercised against Number of securities Exercise price per unit
         

(d)        Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing
e.g. subscription, conversion
Details Price per unit (if applicable)
Ordinary NPV      

4.        OTHER INFORMATION

(a)        Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
None

(b)        Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:
(i)   the voting rights of any relevant securities under any option; or
(ii)   the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state “none”
None

(c)        Attachments

Is a Supplemental Form 8 (Open Positions) attached? No

Date of disclosure: 30/09/2026
Contact name: Callum Ridley – Compliance Department
Telephone number: 0151 243 7037

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at.

LONDON–(BUSINESS WIRE)–  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: NATIXIS SA (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.   (c) Name o

SAN FRANCISCO–(BUSINESS WIRE)–An office lunch can start with a message in Slack and turn into a string of follow-ups: choosing a restaurant, collecting everyone’s order, and checking when the food will arrive. We want to make it easier for the person putting that meal together. Today, we’re introducing a DoorDash connector for corporate ordering. Companies can connect DoorDash to compatible internal AI tools their teams already use, or to agents they build themselves, so employees can arrange

Strategic combination creates a more diversified financial services franchise with greater scale, expanded Mid-Atlantic presence and complementary nationwide businesses

MARIETTA, Ohio, and ROCKVILLE, Md., Sept. 30, 2026 (GLOBE NEWSWIRE) — Peoples Bancorp Inc. (“Peoples”) (NASDAQ: PEBO) and Capital Bancorp, Inc. (“Capital”) (NASDAQ: CBNK) jointly announced today the signing of an agreement and plan of merger (the “Merger Agreement”) pursuant to which Peoples will acquire Capital in an all-stock transaction. Under the terms of the Merger Agreement, Capital will merge with and into Peoples (the “Merger”), and Capital Bank, N.A. will subsequently merge with and into Peoples’ wholly owned subsidiary, Peoples Bank, in a transaction valued at approximately $728.1 million.

Upon completion of the Merger, the combined company is expected to have approximately $14 billion in total assets, $10 billion in total loans and $11 billion in total deposits, with over 150 banking locations across eight states and Washington, D.C., in addition to nationwide specialty financial services platforms.

The combination brings together two diversified financial services franchises with complementary business models and a shared focus on relationship banking. Peoples’ broad platform of community banking, trust and investment services, insurance and specialty financing will be complemented by Capital’s commercial banking franchise in the Washington, D.C. and Baltimore markets, as well as its nationwide businesses in digital consumer credit, government-guaranteed lending and servicing, and residential mortgage banking. Together, the companies expect to create a broader and more diversified revenue mix, additional avenues for growth and greater capacity to serve customers across the combined franchise.

Capital, with four distinct business segments – Commercial Banking, OpenSky™, Windsor Advantage™ and Capital Bank Home Loans – had $3.9 billion in total assets, $3.1 billion in gross loans and $3.4 billion in total deposits as of June 30, 2026. Fee-based revenue represented approximately 22% of Capital’s total revenue in the second quarter of 2026, and Windsor Advantage’s servicing portfolio totaled approximately $3.4 billion.

“As Peoples approached $10 billion in assets, we were deliberate and patient in pursuing the right strategic opportunity,” said Tyler Wilcox, President and Chief Executive Officer of Peoples. “We were looking for a transaction and a partner that strengthens our franchise well beyond scale alone, and Capital does exactly that. Its commercial banking franchise deepens our presence in the attractive Washington, D.C. and Baltimore markets, while OpenSky, Windsor Advantage and Capital Bank Home Loans add complementary nationwide businesses that further diversify our revenue and expand our growth opportunities. Just as importantly, Capital’s entrepreneurial, customer-focused culture aligns well with Peoples. We believe the combination creates a stronger platform for our customers and shareholders, and we look forward to welcoming Capital’s associates, shareholders and clients to Peoples.”

Edward F. “Ed” Barry, Chief Executive Officer of Capital, commented, “Peoples is an excellent strategic partner for Capital because it understands and values the diversified model we built. Our combination pairs Capital’s relationship-driven commercial bank and nationwide specialty businesses with Peoples’ larger balance sheet, broader product capabilities and operating infrastructure. The combination creates meaningful opportunities to serve our customers in more ways, supporting the continued growth of our businesses and providing new opportunities for our employees. We also share a disciplined, relationship-oriented culture, which was an important consideration for us.”

Steven J. Schwartz, Chairman of the Board of Capital, added, “The Capital Board is very fortunate to have an elite group of executives managing and growing the bank. We greatly appreciate their efforts over the years. We believe the merger with Peoples will give the Capital team the added scale and financial resources to continue serving our customers in a first-rate fashion with expanded product offerings and greater capacity. In addition, the transaction delivers compelling value to Capital’s shareholders and positions their investment to benefit from integrating Peoples’ various lines of business, the cost savings achieved through increased size, and the increased liquidity in their shares. Everyone should welcome this incredible opportunity to partner with such a successful enterprise.”

According to the terms of the Merger Agreement, which has been unanimously approved by the Boards of Directors of both companies, shareholders of Capital will receive 1.11 shares of Peoples common stock for each share of Capital common stock. Based on Peoples’ 20-day volume-weighted average closing price of $39.41 per share as of September 29, 2026, the aggregate transaction value is approximately $728.1 million, or $43.75 per share. Former Capital shareholders are expected to collectively own approximately 32% of Peoples following completion of the Merger. The transaction is intended to qualify as a tax-free reorganization for federal income tax purposes.

The transaction is expected to be immediately accretive to Peoples’ estimated earnings in 2027 before one-time costs, with a tangible book value earnback period of under three years and a pro forma return on average tangible common equity of approximately 20%. Pursuant to the Merger Agreement, three members of Capital’s Board of Directors are expected to join the Peoples Board at or promptly following closing, subject to Peoples’ standard corporate governance practices and director evaluation process.

The acquisition is expected to close during the first half of 2027, subject to the satisfaction of customary closing conditions, including regulatory approvals and the approvals of the shareholders of Peoples and Capital.

Raymond James & Associates, Inc. is serving as financial advisor and Dinsmore & Shohl LLP is serving as legal counsel to Peoples. Stephens Inc. is serving as financial advisor and Squire Patton Boggs (US) LLP is serving as legal counsel to Capital.

Conference Call
Peoples intends to conduct a facilitated conference call with analysts, members of the media and investors at 10:00 a.m. Eastern Time on September 30, 2026.  The conference call will consist of prepared commentary from Mr. Wilcox and Katie Bailey, Chief Financial Officer and Treasurer, regarding the planned acquisition, followed by a question and answer period.  The dial-in number for this call will be 1-866-890-9285.  A simultaneous webcast of the conference call audio (listen-only mode) and archived replay will be accessible online via the “Investor Relations” section of Peoples’ website. The audio replay will be available for one year.  Individuals wishing to participate in the live conference call are encouraged to call or sign in at least 15 minutes prior to the scheduled start time.

About Peoples Bancorp Inc.:

Peoples Bancorp Inc. (“Peoples”, NASDAQ: PEBO) is a diversified financial services holding company and makes available a complete line of banking, trust and investment, insurance and specialty financing solutions through its subsidiaries. Headquartered in Marietta, Ohio, since 1902, Peoples has established a heritage of financial stability, growth and community impact. Peoples had $9.5 billion in total assets as of June 30, 2026, and 144 locations, including 127 full-service bank branches in Ohio, West Virginia, Kentucky, Virginia, Washington, D.C., and Maryland. Peoples’ vision is to be the Best Community Bank in America.

Peoples is a member of the Russell 3000 index of United States publicly-traded companies. Peoples offers services through Peoples Bank (which includes the divisions of Peoples Investment Services, Peoples Premium Finance and North Star Leasing), Peoples Insurance Agency, LLC, and Vantage Financial, LLC.

About Capital Bancorp, Inc.:

Capital Bancorp, Inc., Rockville, Maryland is a registered bank holding company incorporated under the laws of Maryland. Capital Bancorp has been providing financial services since 1999 and now operates bank branches in four locations in the Washington, D.C., and Baltimore, Maryland, metropolitan markets, one bank branch in Fort Lauderdale, Florida, one bank branch in Chicago, Illinois, and one bank branch in Raleigh, North Carolina. Capital Bancorp had assets of approximately $3.9 billion at June 30, 2026 and its common stock is traded in the NASDAQ Global Market under the symbol “CBNK.”

Forward-Looking Statements

This communication includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, which statements involve inherent risks and uncertainties. Examples of forward-looking statements include, but are not limited to, statements regarding the outlook and expectations of Peoples and Capital, respectively, with respect to the proposed transaction, the strategic and financial benefits of the proposed transaction, including the expected impact of the proposed transactions on the combined company’s future financial performance (including anticipated accretion to earnings per share, the tangible book value earn-back period, and other operating and return metrics), the timing of the closing of the proposed transaction, and the ability to successfully integrate the combined businesses. Such statements are often characterized by the use of qualified words (and their derivatives) such as “may,” “will,” “anticipate,” “could,” “should,” “would,” “believe,” “contemplate,” “expect,” “estimate,” “continue,” “plan,” “project,” and “intend,” as well as words of similar meaning or other statements concerning opinions or judgment of Peoples or Capital or their respective management about future events. Forward-looking statements are based on assumptions as of the time they are made and are subject to risks, uncertainties, and other factors that are difficult to predict with regard to timing, extent, likelihood, and degree of occurrence, which could cause actual results to differ materially from anticipated results expressed or implied by such forward-looking statements. Such risks, uncertainties and assumptions include, among others, the following:

  • the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the Merger Agreement;
  • the failure to obtain necessary regulatory approvals (and the risk that such approvals may result in the imposition of conditions that could adversely affect the combined company or the expected benefits of the proposed transaction) and the possibility that the proposed transaction does not close when expected or at all because required regulatory approvals, the failure to obtain required shareholder approvals, or other approvals and the other conditions to closing are not received or satisfied on a timely basis or at all;
  • the outcome of any legal proceedings that may be instituted against Peoples or Capital;
  • the possibility that the anticipated benefits of the proposed transaction, including anticipated cost savings and strategic gains, are not realized when expected or at all, including as a result of changes in, or problems arising from, general economic and market conditions, interest and exchange rates, monetary policy, laws and regulations and their enforcement, and the degree of competition in the geographic and business areas in which Peoples and Capital operate;
  • the possibility that integration of the companies may be more difficult, time-consuming, or costly than expected;
  • the impact of purchase accounting with respect to the proposed transaction, or any change in the assumptions used regarding the assets acquired and liabilities assumed to determine their fair value and credit marks;
  • the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events;
  • the diversion of management’s attention from ongoing business operations and opportunities;
  • potential adverse reactions of Peoples’ or Capital’s customers or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction;
  • a material adverse change in the financial condition of Peoples or Capital;
  • changes in Peoples’ share price before closing;
  • risks relating to the potential dilutive effect of shares of Peoples’ common stock to be issued in the proposed transaction;
  • general competitive, economic, political, and market conditions;
  • major catastrophes such as earthquakes, floods, or other natural or human disasters, including infectious disease outbreaks; and
  • other factors that may affect future results of Peoples or Capital, including, among others, changes in asset quality and credit risk; the inability to sustain revenue and earnings growth; changes in interest rates; deposit flows; inflation; customer borrowing, repayment, investment, and deposit practices; the impact, extent, and timing of technological changes; capital management activities; and other actions of the Federal Reserve Board, the Office of the Comptroller of the Currency, the Consumer Financial Protection Bureau, and legislative and regulatory actions and reforms.

These factors are not necessarily all of the factors that could cause Peoples, Capital, or the combined company’s actual results, performance, or achievements to differ materially from those expressed in or implied by any of the forward-looking statements. Other factors, including unknown or unpredictable factors, also could harm Peoples’, Capital’s, or the combined company’s results. 

Although each of Peoples and Capital believes that its expectations with respect to forward-looking statements are based upon reasonable assumptions within the bounds of its existing knowledge of its business and operations, there can be no assurance that actual results of Peoples or Capital will not differ materially from any projected future results expressed or implied by such forward-looking statements. Additional factors that could cause results to differ materially from those described above can be found in each of Peoples’ and Capital’s most recent annual report on Form 10-K for the fiscal year ended December 31, 2025, quarterly reports on Form 10-Q, and other documents subsequently filed by Peoples and Capital with the Securities and Exchange Commission. The actual results anticipated may not be realized or, even if substantially realized, they may not have the expected consequences to or effects on Peoples, Capital, or each of their respective businesses or operations. Investors are cautioned not to rely too heavily on any such forward-looking statements. Peoples and Capital urge you to consider all of these risks, uncertainties, and other factors carefully in evaluating all such forward-looking statements made by Peoples and Capital. Forward-looking statements speak only as of the date they are made, and Peoples and Capital undertake no obligation to update or clarify these forward-looking statements, whether as a result of new information, future events, or otherwise, except to the extent required by applicable law.

Additional Information and Where to Find It

In connection with the proposed transaction, Peoples intends to file with the SEC a Registration Statement on Form S-4 to register the shares of Peoples common stock to be issued in connection with the proposed transaction. The Registration Statement will include a joint proxy statement/prospectus, and Peoples and Capital may file with the SEC other relevant documents concerning the proposed transaction. The information contained herein does not constitute an offer to sell or a solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE REGISTRATION STATEMENT AND JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION WHEN THEY BECOME AVAILABLE AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PEOPLES, CAPITAL, AND THE PROPOSED TRANSACTION AND RELATED MATTERS.

Investors and security holders will be able to obtain a free copy of the registration statement, including the joint proxy statement/prospectus, as well as other relevant documents filed with the SEC containing information about Peoples and Capital, without charge, at the SEC’s website (https://www.sec.gov).

Participants in Solicitation

Peoples and Capital, along with their respective directors, executive officers, management, and employees may be deemed participants in the solicitation of proxies in connection with the Merger. Information concerning Peoples’ participants is set forth in the Proxy Statement, dated March 6, 2026, for Peoples’ 2026 annual meeting of stockholders as filed with the SEC on Schedule 14A. Information concerning Capital’s participants is set forth in the Proxy Statement, dated April 7, 2026, for Capital’s 2026 annual meeting of stockholders as filed with the SEC on Schedule 14A. Additional information regarding the participants in the solicitation of proxies in respect of the proposed transaction and interests of participants of Peoples and Capital in the solicitation of proxies in respect of the Merger will be included in the registration statement and joint proxy statement/prospectus to be filed with the SEC. Free copies of these documents, when available, may be obtained as described in the preceding paragraph.

Contacts: Tyler J. Wilcox Edward F. Barry
  President and Chief Executive Officer Chief Executive Officer
  Peoples Bancorp Inc. Capital Bancorp, Inc.
  (740) 373-7737 (301) 468-8848
     
  Katie Bailey Jacob Dalaya
  Chief Financial Officer and Treasurer Chief Financial Officer
  (740) 376-7138 (301) 637-5118

Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software

SARASOTA, FLA., Sept. 30, 2026 (GLOBE NEWSWIRE) — Silo Pharma (Nasdaq: SILO) (“Silo” or “the Company”), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems with a wholly owned managed AI agent subsidiary QwikAgents, today announced that QwikAgents has expanded its AI agent platform with new customer choice across both AI models and agent software, including support for customer-supplied NVIDIA API keys and the addition of Hermes agent runtime. The new capabilities are available now and are designed to provide customers greater flexibility in how their AI agents are configured and operated.

The addition of NVIDIA support builds on QwikAgents’ participation in the NVIDIA Developer Program, which began in July 2026. Customers can now connect their own NVIDIA API keys to QwikAgents to access NVIDIA’s Nemotron models, with automated model routing designed to maintain agent availability. NVIDIA becomes the fifth supported bring-your-own-key provider on the QwikAgents platform, alongside Anthropic, OpenAI, Google and DeepSeek.

At the agent software layer, QwikAgents has added Hermes agent runtime as an alternative to OpenClaw runtime, allowing customers to select between the two when creating an agent. An agent runtime is the software that reads customer instructions, calls language models and carries out assigned tasks. Both runtime options operate on QwikAgents’ underlying infrastructure, including managed hosting, persistent memory, model routing and dedicated compute.

“AI models and agent software are both evolving rapidly, and we believe customers should have the flexibility to choose the technologies that best fit their needs rather than be locked into a single provider or runtime,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. “By adding NVIDIA model support and a second agent runtime, we are expanding QwikAgents as a flexible platform that can evolve with the AI ecosystem while providing customers with a consistent managed infrastructure. We expect to continue broadening the models and runtimes available through the platform over time.”

About Silo Pharma, Inc.

Silo Pharma is a diversified developmental-stage biopharmaceutical company with a therapeutic focus on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and chronic pain, and a preclinical asset targeting Alzheimer’s disease. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com

QwikAgents, Silo Pharma’s wholly owned artificial intelligence subsidiary, is a managed AI agent platform that delivers dedicated autonomous agents for research, content generation, scheduling, and workflow automation each running in a persistent environment with proprietary smart-routing across multiple AI models. The subsidiary reflects Silo’s strategy to expand into high-growth technology markets while continuing to advance its core biopharmaceutical pipeline. qwikagents.com

Forward Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including statements about changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact

(800) 705-0120
investors@silopharma.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.